A Novel Sequentially Evolved
ALK+ NSCLC
Double mutation
G1202R
Lorlatinib resistance
S1206Y
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
18
09
2020
revised:
08
10
2020
accepted:
25
10
2020
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
1
10
2021
Statut:
epublish
Résumé
Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired
Identifiants
pubmed: 34589977
doi: 10.1016/j.jtocrr.2020.100116
pii: S2666-3643(20)30162-4
pmc: PMC8474455
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100116Informations de copyright
© 2020 The Authors.
Références
Clin Cancer Res. 2019 Nov 15;25(22):6671-6682
pubmed: 31439588
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620935770
pubmed: 32600123
J Thorac Oncol. 2017 Jan;12(1):137-140
pubmed: 27666659
J Thorac Oncol. 2019 Nov;14(11):e257-e259
pubmed: 31668326
EBioMedicine. 2019 Mar;41:105-119
pubmed: 30662002
J Thorac Oncol. 2020 Feb;15(2):258-265
pubmed: 31669591
J Clin Oncol. 2019 Jun 1;37(16):1370-1379
pubmed: 30892989
N Engl J Med. 2016 Jan 7;374(1):54-61
pubmed: 26698910
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
Cancer Cell. 2015 Jul 13;28(1):70-81
pubmed: 26144315
N Engl J Med. 2020 Nov 19;383(21):2018-2029
pubmed: 33207094
J Thorac Oncol. 2020 Sep;15(9):1484-1496
pubmed: 32360579
Clin Cancer Res. 2019 Nov 15;25(22):6662-6670
pubmed: 31358542
Lung Cancer. 2016 Jan;91:70-2
pubmed: 26464158
Cancer Discov. 2018 Jun;8(6):714-729
pubmed: 29650534
Clin Cancer Res. 2020 Jan 1;26(1):242-255
pubmed: 31585938
J Thorac Oncol. 2019 Nov;14(11):1901-1911
pubmed: 31446141
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378